Although human epidermal growth factor receptor type 2 (HER2)-positive breast cancers have a poor prognosis [5], the development of therapeutic monoclonal antibodies against HER2 receptor has drastically improved the prognosis of such breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.